-
Patent Agency Ranking
公开(公告)号：US20180086716A1
公开(公告)日：2018-03-29
申请号：US15711984
申请日：2017-09-21
Applicant: NOVARTIS AG
Inventor： Badry BURSULAYA , Andreas FISCH , James Paul LAJINESS , Rainer MACHAUER , Swapnil MALEKAR , Hank Michael James PETRASSI , Farshad RAMAZANI , Anne-Catherine REMOND , Thomas ULLRICH , Peggy USSELMANN , Eric VANGREVELINGHE
IPC: C07D231/56 , A61K9/16 , A61K9/00 , C07D403/12 , A61K31/416 , C07D401/12 , A61K31/454 , C07D405/12
CPC classification number: C07D231/56 , A61K9/0019 , A61K9/1647 , A61K31/416 , A61K31/454 , C07D401/12 , C07D403/12 , C07D405/12
Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
公开(公告)号：US20180273522A1
公开(公告)日：2018-09-27
申请号：US15762724
申请日：2016-09-20
Applicant: Novartis AG
Inventor： Eric AUBIN , Anthony CASAREZ , Andreas FISCH , Zaixing LI , Mika LINDVALL , Heinz Ernst MOSER , Michael MUTZ , Folkert RECK , Bernd Ulrich RIEBESEHL , Marc SCHOENHENTZ , Vijay SETHURAMAN , Robert Lowell SIMMONS
IPC: C07D417/14 , A61P31/04
CPC classification number: C07D417/14 , A61P31/04 , C07B2200/13
Abstract: The invention provides new solid forms, salts and polymorphs of 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3-yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), pharmaceutical compositions containing them, and processes for their manufacture and use in therapy.
-
公开(公告)号：US20240269279A1
公开(公告)日：2024-08-15
申请号：US18569346
申请日：2022-06-14
Applicant: NOVARTIS AG
Inventor： Ivan BOTTOLLI , Andreas FISCH
CPC classification number: A61K39/39566 , A61K9/08 , A61K39/39591 , A61K47/183 , A61K47/22 , A61K47/26 , C07K16/4291 , A61K2039/505 , C07K2317/94
Abstract: The present invention provides anti-lgE antibodies formulated as stable aqueous pharmaceutical compositions. suitable for injection. An aqueous pharmaceutical composition of the invention includes a sugar (trehalose). a buffering agent (histidine). and a surfactant (polysorbate 20). The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody (at least 50 mg/ml) active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter.
-
公开(公告)号：US20210188842A1
公开(公告)日：2021-06-24
申请号：US16941395
申请日：2020-07-28
Applicant: NOVARTIS AG
Inventor： Badry BURSULAYA , Andreas FISCH , James Paul LAJINESS , Rainer MACHAUER , Swapnil MALEKAR , Hank Michael James PETRASSI , Farshad RAMAZANI , Anne-Catherine REMOND , Thomas ULLRICH , Peggy USSELMANN , Eric VANGREVELINGHE
IPC: C07D471/04 , A61P21/00 , A61K9/00 , A61K9/50 , A61K31/437 , A61K31/496 , A61K31/538
Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
公开(公告)号：US20190300522A1
公开(公告)日：2019-10-03
申请号：US16335496
申请日：2017-09-21
Applicant: NOVARTIS AG
Inventor： Badry BURSULAYA , Andreas FISCH , James Paul LAJINESS , Rainer MACHAUER , Swapnil MALEKAR , Hank Michael James PETRASSI , Farshad RAMAZANI , Anne-Catherine REMOND , Thomas ULLRICH , Peggy USSELMANN , Eric VANGREVELINGHE
IPC: C07D471/04 , A61K9/00 , A61K9/50 , A61P21/00 , A61K31/437 , A61K31/538 , A61K31/496
Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
-
-
-
Search Results
5
records
(took 0.015 seconds)
